Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Pay-For-Delay Ruling Against Lundbeck Sends Signal To Others, Including UK Competition Body

Executive Summary

The EU’s General Court has upheld the European Commission’s decision to fine Lundbeck and a number of generics firms for agreeing to keep generic versions of the antidepressant citalopram off the market in return for payments. The ruling could have implications for other similar cases such as that involving GlaxoSmithKline’s paroxetine in the UK.

You may also be interested in...



CJEU Opinion Backs Lundbeck Fine Over Citalopram ‘Pay For Delay’ Deals

A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.

UK Wants European Court's View On Paroxetine Pay-For-Delay Case

A referral in the long-running paroxetine pay-for-delay case will see the Court of Justice of the EU give preliminary rulings on a number of competition issues such as abuse of a dominant position, the relevant product market, and restrictions of competition by object and by effect.

UK Wants European Court's View On Paroxetine Pay-For-Delay Case

A referral in the long-running paroxetine pay-for-delay case will see the Court of Justice of the EU give preliminary rulings on a number of competition issues such as abuse of a dominant position, the relevant product market, and restrictions of competition by object and by effect.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel